That research isn’t conclusive yet, said Paul Hutson, a professor at the University of Wisconsin-Madison who studies psilocybin and leads the school’s center for psychedelics research. But he anticipates there will soon be enough evidence for the Food and Drug Administration to approve psilocybin capsules to treat at least some of these disorders — most likely in the next five years or so.
The term “‘disability’ is not a slur,” says Morton Ann Gernsbacher, PhD, a psychology professor at the University of Wisconsin-Madison who studies how language is used in relation to disability. But the term “special needs” may be moving in that direction, she says.
‘Dry January’ is a New Year’s resolution where participants go alcohol-free for the first month of the year, and UW Health has tips to help you keep that resolution.
UW Health’s Dr. Jeffery Pothof says the hospital is at 100% capacity, “trading patient for patient,” as it tries to help everyone coming to its doors.
Children’s hospitals, including one in Madison, are strained with children fighting coronavirus, and a mix of factors explains why kids are the latest targets of the pandemic. “We’ve had more kids with COVID in the last couple of months, and certainly in the last month, that I can recall at any point in the pandemic,” said Dr. James Conway, a pediatric infectious disease physician and medical director of UW Health’s immunization program.
The University of Wisconsin men’s hockey team postponed games against No. 17 Ohio State set for Friday and Saturday because of at least one COVID-19 case within the Badgers program.
Nearly two years into the global COVID-19 pandemic and with cases once again surging, UW Health’s chief quality officer is warning the next few weeks could be grim.
The concentration in meatpacking also serves as a deterrent to farmers who might want to sell to the new government funded startups — who know “they are unlikely to be welcomed back if the buyer fails,” said University of Wisconsin law professor and former Department of Justice antitrust attorney Peter Carstensen.
That research isn’t conclusive yet, said Paul Hutson, a professor at the University of Wisconsin-Madison who studies psilocybin and leads the school’s center for psychedelics research. But he anticipates there will soon be enough evidence for the Food and Drug Administration to approve psilocybin capsules to treat at least some of these disorders — most likely in the next five years or so.
